Edition:
United States

Aevi Genomic Medicine Inc (GNMX.OQ)

GNMX.OQ on NASDAQ Stock Exchange Global Market

1.16USD
9:43am EST
Change (% chg)

$0.01 (+0.87%)
Prev Close
$1.15
Open
$1.16
Day's High
$1.16
Day's Low
$1.16
Volume
2,772
Avg. Vol
62,425
52-wk High
$6.17
52-wk Low
$0.98

Chart for

About

Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The... (more)

Overall

Beta: 0.42
Market Cap(Mil.): $68.23
Shares Outstanding(Mil.): 59.33
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Aevi Genomic Medicine Files For Resale Of Up To 26.2 Mln Shares Of Co's Common Stock By Selling Stockholders

* AEVI GENOMIC MEDICINE INC FILES FOR RESALE OF UP TO 26.2 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text - http://bit.ly/2kEddlX Further company coverage:

Dec 08 2017

BRIEF-Aevi Genomic Medicine Announces New Appointment To Its Board Of Directors

* AEVI GENOMIC MEDICINE ANNOUNCES NEW APPOINTMENT TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Dec 04 2017

BRIEF-Aevi Genomic Medicine Q3 loss per share $0.23

* Aevi Genomic Medicine reports third quarter 2017 financial results

Nov 02 2017

BRIEF-Aevi Genomic Medicine announces private placement

* Aevi Genomic Medicine announces agreement for $28 million private placement

Aug 10 2017

BRIEF-Aevi Genomic Medicine reports Q2 loss per share of $0.22

* Aevi Genomic Medicine reports second quarter 2017 financial results

Aug 09 2017

BRIEF-Aevi Genomic Medicine reprts qtrly loss per share of $0.22

* Qtrly diluted loss per share $0.22 Source text for Eikon: Further company coverage:

Aug 09 2017

Earnings vs. Estimates